Our Pipeline

As we evolve with our science, our multifaceted approach builds a robust pipeline of patient direct therapies.

At Ikena™, we are advancing a portfolio of targeted therapies intended to enable a personalized approach for every patient with cancer.

Our Pipeline

Discovery

IND Enabling

Phase 1

Late-Stage
Development

Partnerships & Rights

Targeted Oncology
Hippo Signaling Pathway

IK-930
TEAD

Hippo-altered Cancers
Monotherapy & Multiple Combinations

Phase 1
Ikena Oncology Logo

Undisclosed

Hippo-altered Cancers

IND Enabling
Ikena Oncology Logo
RAS Pathway

IK-595
MEK-RAF

RAS and RAF altered cancers; additional tumor types

IND Enabling
Ikena Oncology Logo

Undisclosed

RAS-mutated Cancers

IND Enabling
Ikena Oncology Logo
Immune-Signaling
AHR Signaling
IK-175
AHR
Bladder Cancer, AHR Enriched
Monotherapy & Nivolumab Combination
Phase 1
Head & Neck Cancer, AHR Enriched
Nivolumab Combination
Phase 1

EP4 Signaling

IK-007
EP4

MSS-CRC, PGEM Enriched
Pembrolizumab Combination

Phase 1
Ikena Oncology Logo

Targeted Oncology Programs in the Hippo and RAS Signaling Pathways

Our targeted oncology discovery efforts include programs that target the Hippo and RAS pathways, emphasizing our philosophy of designing treatments for tailored patient populations that are identified through the genetic makeup of their tumors. Our lead program, IK-930, targets the key TEAD transcription factor in the Hippo pathway. Across IK-930 and our preclinical pipeline, extensive translational data accompany our strategic development for each target, and we continue to generate data to identify biomarker-defined, underserved cancer patient populations.

The Hippo Signaling Pathway

As a key driver of cancer pathogenesis, the Hippo pathway regulates cell fate, proliferation, and survival. The pathway is genetically altered in approximately 10% of all human cancers. In certain tumors, the genetic alterations in the Hippo pathway can be as frequent as 40%, for example as in malignant Mesothelioma, and in epithelioid hemangioendothelioma (EHE), a rare type of soft tissue sarcoma, where 100% of patients have key Hippo pathway fusion genes.

The Hippo pathway is also implicated in therapeutic resistance, potentially providing compensatory growth and survival signals in tumors when patients are treated with other therapies. Resistance to multiple targeted therapies and tumor recurrence can be linked to YAP/TEAD activation. Overcoming resistance mechanisms can deepen and prolong responses.

Hippo Signaling Pathway Alterations and Activity Trigger Tumor Growth

Hippo Illustration

IK-930: TEAD Inhibitor

IK-930 binds to TEAD transcription factors near the end of the Hippo pathway and prevents the expression of multiple target genes that drive cancer progression, metastases, and therapeutic resistance. We are exploring the potential of IK-930 both as a monotherapy in patients with Hippo pathway-mutated cancers and in combination with other targeted therapies.

The RAS Signaling Pathway

The RAS pathway is a well-known cancer-driving pathway that is mutated in approximately 30% of all human cancers. For decades, the RAS pathway was considered undruggable. Despite advancements in recent years targeting RAS-mutated cancers, approximately 85% of RAS mutations are not addressed by current product candidates or approved therapies. We believe that the key to addressing the unmet need for patients with these mutations is to target the pathway on multiple levels and understand the resistance mechanism to achieve deep and sustained responses.

Exploring Addressable Targets in the RAS Signaling Pathway

IKENA PipelinePage Graphics

Immune Signal Targeting Programs in Tumor Microenvironment Modulation

AHR Inhibition

Activated aryl hydrocarbon receptors (AHR) prevent immune recognition in a range of cancers by modulating both innate and adaptive immunity. AHR activity has been linked to multiple cancer types, including bladder cancer, head and neck cancer, melanoma, malignant gliomas, and acute myeloid leukemia (AML).

AHR Signaling

AHR Signaling Illustration

IK-175: AHR Antagonist

IK-175 targets AHR, a compelling cancer-driving transcription factor. IK-175 offers a new opportunity for patients who cannot benefit from current standard-of-care treatments. A body of translational data, including data generated with our internally discovered biomarkers and novel assays, has identified multiple cancers in which AHR is activated, including bladder cancer and head and neck cancer. We are exploring IK-175 as a monotherapy and in combination with nivolumab.

Interested in reading more about the science behind Ikena?

Scroll to Top